The recent discovery of new genetic or epigenetic vulnerabilities specific to cancer, including components of the SWI/SNF complex, has the potential to improve precision medicine and the development of targeted anti-cancer therapies [203]. This evidence concerns the gene SMARCA1 and cancer.